Thymosin Alpha-1: Dosing Protocols

Research Dosing Disclaimer#

The dosing information presented here is derived from published clinical trials, approved prescribing information for Zadaxin (thymalfasin) in countries where it is registered, and peer-reviewed medical literature. This information is provided for educational and research reference purposes only and does not constitute medical advice or a recommendation for self-administration. Thymosin Alpha-1 is not approved by the US Food and Drug Administration (FDA) or the European Medicines Agency (EMA). Any clinical use should be under the direct supervision of a qualified healthcare provider in accordance with applicable local regulations.

Approved Dosing Protocols#

Standard Hepatitis B Regimen#

The most extensively studied and regulatory-approved dosing regimen for Thymosin Alpha-1 is the standard Zadaxin protocol for chronic hepatitis B virus infection. This regimen consists of 1.6 mg thymalfasin administered by subcutaneous injection twice weekly, with injections separated by approximately 3 to 4 days (e.g., Monday and Thursday, or Tuesday and Friday scheduling).

The standard treatment duration is 6 months (approximately 52 injections), though clinical data support extending treatment to 12 months in patients who show partial response or delayed seroconversion. A distinctive feature of Ta1 therapy is that sustained virological response rates continue to increase after treatment cessation, with response rates at 6 and 12 months post-treatment exceeding end-of-treatment response rates. This delayed and sustained response pattern reflects the immune-mediated mechanism of action, where Ta1-induced immune reconstitution provides durable viral control that outlasts the period of drug administration.

In randomized controlled trials, this regimen achieved sustained virological response rates (defined as HBV DNA suppression and HBeAg seroconversion) of 26-36% at 12 months post-treatment, compared to 10-16% in untreated control groups. When combined with interferon-alpha, sustained response rates reached 40-50%.

Immune Reconstitution Protocol#

For patients with immunodeficiency or immunosenescence requiring general immune support, the standard 1.6 mg twice-weekly subcutaneous regimen is typically employed. Treatment duration is more variable than in the hepatitis indication and is guided by clinical response, immune biomarker monitoring, and the underlying condition being treated.

Clinical monitoring parameters during immune reconstitution therapy typically include:

• CD4+ and CD8+ T-cell counts and CD4/CD8 ratio
• Natural killer (NK) cell counts and cytotoxicity assays
• Serum immunoglobulin levels
• Specific pathogen serologies or viral loads as clinically indicated
• General markers of immune function such as delayed-type hypersensitivity (DTH) responses

In elderly patients receiving Ta1 for immunosenescence, treatment courses of 3 to 6 months have been evaluated in clinical studies. In vaccine adjuvant applications, shorter courses (2-4 weeks surrounding vaccination) have been used to enhance seroconversion rates.

Cancer Adjuvant Dosing#

In cancer immunotherapy adjunct trials, higher-frequency dosing has been investigated, typically 1.6 mg subcutaneous daily (rather than twice weekly) during active chemotherapy cycles. This intensified schedule aims to counteract the acute immunosuppressive effects of cytotoxic chemotherapy and maintain anti-tumor immune surveillance during treatment.

Specific cancer adjuvant protocols from published clinical trials include:

• Hepatocellular carcinoma with TACE: 1.6 mg subcutaneous daily for 5 consecutive days, repeated with each TACE cycle, followed by twice-weekly maintenance
• Non-small cell lung cancer with platinum chemotherapy: 1.6 mg subcutaneous daily for 7 days surrounding each chemotherapy cycle (starting 2 days before through 5 days after)
• General cancer adjuvant: 1.6 mg subcutaneous daily during the first week of each chemotherapy cycle, then twice weekly between cycles

These cancer adjuvant protocols represent investigational use and have not received the same level of regulatory validation as the standard hepatitis B regimen. The optimal frequency, timing relative to chemotherapy, and total treatment duration for cancer adjuvant use have not been established through formal dose-optimization studies.

Sepsis Protocol#

In the ETASS (Efficacy of Thymosin Alpha 1 for Severe Sepsis) trial, the dosing regimen was 1.6 mg subcutaneous daily for 7 consecutive days, initiated within 72 hours of sepsis diagnosis. This higher-frequency short-course regimen targets the immunosuppressive phase of sepsis, aiming to reverse sepsis-induced immunoparalysis and reduce susceptibility to secondary infections. This protocol remains investigational and has not received regulatory approval for sepsis.

Administration Routes#

Subcutaneous Injection#

The approved and clinically validated route of administration for Thymosin Alpha-1 is subcutaneous (SC) injection. The 1.6 mg dose is administered as a single SC injection using a standard insulin-type syringe (25-29 gauge, 0.5 to 1 inch needle length).

Recommended injection sites include:

• Anterior abdomen: The preferred site, at least 2 inches from the navel, avoiding the belt line. The abdomen provides consistent absorption and is easily accessible for self-administration.
• Anterior thigh: The middle third of the outer thigh, offering an alternative site for rotation.
• Upper arm: The posterior upper arm (deltoid region), useful for injection site rotation, though self-injection at this site may be challenging.

Injection site rotation is recommended to minimize local irritation and ensure consistent absorption. Patients should be instructed to alternate between at least two anatomical sites, and within each site, to vary the exact injection point by at least 1 inch from previous injections.

Injection Technique#

The standard technique for subcutaneous administration involves:

1. Reconstitute the lyophilized powder with the provided sterile water for injection
2. Inspect the reconstituted solution for clarity and absence of particulate matter
3. Draw the full reconstituted volume into a sterile syringe
4. Clean the injection site with an alcohol swab and allow to dry
5. Pinch a fold of skin at the chosen injection site
6. Insert the needle at a 45-90 degree angle (depending on needle length and subcutaneous tissue depth)
7. Inject the full volume slowly and steadily
8. Withdraw the needle and apply gentle pressure with a gauze pad; do not massage the injection site

No intravenous, intramuscular, or other parenteral routes have been validated for clinical use. Oral administration is not effective due to peptide degradation in the gastrointestinal tract.

Storage Guidelines#

Lyophilized Product Storage#

Thymosin Alpha-1 in its lyophilized (freeze-dried) pharmaceutical form requires refrigerated storage at 2-8 degrees Celsius (36-46 degrees Fahrenheit). The product should be protected from direct light exposure and stored in its original packaging until use. Under these conditions, the lyophilized powder maintains stability and potency for up to 24 months from the date of manufacture.

The product should not be frozen, as freeze-thaw cycles may compromise the integrity of the lyophilized cake structure and affect reconstitution properties. Brief excursions to room temperature (up to 25 degrees Celsius for limited periods during transport) are generally tolerable, but prolonged storage at ambient temperature is not recommended and may reduce shelf life.

Reconstituted Solution#

Once reconstituted with sterile water for injection, the solution should be used immediately. The reconstituted product does not contain preservatives and should not be stored for later use. Any unused portion must be discarded following standard medical waste procedures. Do not re-lyophilize or re-freeze reconstituted solution.

Research-Grade Peptide Storage#

For research applications using non-pharmaceutical grade thymosin alpha-1, the following storage practices apply:

• Lyophilized powder: Store at -20 degrees Celsius for long-term storage (months to years). Desiccant should be included to prevent moisture exposure. Allow vial to reach room temperature before opening to prevent condensation.
• Reconstituted stock solutions: Store aliquots at -20 degrees Celsius or below. Avoid repeated freeze-thaw cycles by preparing single-use aliquots. Reconstitute in sterile bacteriostatic water or appropriate buffer for the intended application.
• Working solutions: Prepare fresh on the day of use when possible. Aqueous solutions at refrigerated temperature (2-8 degrees Celsius) are generally stable for up to 48 hours but should be verified for the specific formulation and buffer system used.

Tools & Resources#

Calculate your exact dose -- Use the Dosing Calculator to convert vial concentrations to injection volumes for Thymosin Alpha-1.

Plan your bloodwork -- Build a pre-protocol blood panel with the Bloodwork Planner to track immune markers during your Thymosin Alpha-1 cycle.

Check stack compatibility -- Verify Thymosin Alpha-1 interactions with your other peptides using the Stack Compatibility Checker.

Related Dosing Guides#

• LL-37 Dosing Protocols -- Another immune-modulating peptide
• Thymalin Dosing Protocols -- Related thymic peptide with different dosing approach

Compare Thymosin Alpha-1#

• Thymosin Alpha-1 vs LL-37 -- Immune peptide comparison
• Thymosin Alpha-1 vs Thymalin -- Thymic peptide head-to-head

Related Reading#

• Thymosin Alpha-1 overview and research guide
• Thymosin Alpha-1 side effects profile
• Thymosin Alpha-1 research evidence